The clinical trial with type 1 diabetes mellitus (T1DM) subjects treated with the same fixed combination (Berberol®) showed decreasing of insulin dose necessary to reach adequate glycemic control [144]. This evidence concerns the gene INS and type 1 diabetes mellitus.